



Integra LifeSciences Announces Determination of Entitlement to Contingent Interest On Convertible Notes Due 2008

PLAINSBORO, N.J., Feb 20, 2008 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has determined that holders of its 2 1/2% Contingent Convertible Subordinated Notes due 2008 ("Notes") shall be entitled to receive contingent interest on March 17, 2008 in accordance with the terms of the Notes. The amount of contingent interest that will be payable is \$15.00 per \$1,000 principal amount of Notes.

Wells Fargo will be acting as the Conversion Agent for these notes. Questions regarding redemption can be referred to Wells Fargo Bondholder Communications at 1-800-344-5128.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the expectations, plans and prospects for the Company. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-F

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President, Chief
Administrative Officer, Acting Chief Financial Officer
(609) 936-2481

jhenneman@Integra-LS.com

Karen Mroz-Bremner, Manager, Corporate Development,
and Investor Relations

(609) 936-6929

karen.mroz-bremner@integra-LS.com

(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX